Биохимическая и молекулярно-биологическая характеристика штаммов микобактерий туберкулезного комплекса, распространенных в Санкт-Петербурге

5. ВЫВОДЫ.

1. Секвенирование фрагментов генома санкт-петербургских изолятов M. tuberculosis показало:

— точечные мутации, обнаруженные в генах кatG и гроВ среди 93 и 88% INH-и RIF-устойчивых изолятов, соответственно, являются надежными маркерами устойчивости к данным препаратам;

— детекция мутаций в области QRDR гена gyrA позволяет обнаружить не менее 50% OFL-устойчивых изолятов;

— область QRDR гена gyrB не имела мутаций, ассоциированных с устойчивостью к OFL, в исследованной группе изолятов.

2. Генотипирование штаммов М. tuberculosis на основе полиморфизма области прямых повторов выявило доминирование генетического семейства Beijing во всех исследованных группах изолятов. Исследованные штаммы семейства Beijing достоверно чаще (р<0,05) обладали МЛУ, устойчивостью к OFL, а также значительно чаще преобладали среди пациентов, находящихся в местах лишения свободы, чем штаммы других генотипов.

3. Впервые показано распространение генетически сходных изолятов M. tuberculosis среди бездомных, ВИЧ-инфицированных и пациентов из общей популяции жителей Санкт-Петербурга. Сравнение сполиготипов исследованных штаммов МБТ обнаружило более низкое генетическое разнообразие бактериальных штаммов, выявленных среди заключенных, а также среди OFL-устойчивых изолятов.

4. Сформирована коллекция образцов геномной ДНК клинических штаммов M. tuberculosis, полученных от больных туберкулезом жителей Санкт-Петербурга, необходимая для создания кандидатного вакцинового препарата, направленного на профилактику и лечение туберкулезной инфекции. Данная коллекция образцов может быть использована для разработки тест-систем по обнаружению лекарственно-устойчивых штаммов МБТ.

1. Белиловский Е. Государственная система мониторинга туберкулеза в России / Е. Белиловский, С. Борисов, А. Гордина и соавт // Новые информационные технологии и мониторинг туберкулеза в России. 2000. — С. 10−30.

2. Туберкулез в Российской Федерации 2006 г.: Аналитический обзор основных статистических показателей по туберкулезу, используемых в Российской Федерации // М.: «Минздрав-соцразвития Российской Федерации», ЦНИИОИЗ 2007.

3. Туберкулез в Российской Федерации 2007 г.: Аналитический обзор основных статистических показателей по туберкулезу, используемых в Российской Федерации // М.: «Минздрав-соцразвития Российской Федерации», ЦНИИОИЗ 2008.

4. Туберкулез. Патогенез, защита, контроль. Под ред. Б. Р. Блума. М.: Медицина, 2002. с. 292−293.

5. Федеральный Центр мониторинга противодействия распространению туберкулеза в РФ, ФГУ «ЦНИИОИЗ» 2010. http. V/www.tbpolicy.ru/statistic/national/- дата обращенияапрель 2011 г.

6. AFEW. Aids Foundation East West. Officially registered HIV cases in the Russian federation 1 January 1987 through 1 June 2004. Amsterdam, The Netherlands: www.afew.org/ english/countries/russia.php Accessed October 2004.

7. Agerton T. Spread of strain W, a highly drug-resistant strain of Mycobacterium tuberculosis, across the United States / T. Agerton, S. Valway, R. Blinkhorn et al. // Clin. Infect. Dis.1999. V.29. — P.85−92.

8. AIDS Wkly. Co-infection (HIV/ТВ): Dual epidemic is developing in Russia // AIDS Wkly2000. P8.

9. Alangaden G. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis / G. Alangaden, B. Kreiswirth, A. Aouad et al. // Antimicrob. Agents Chemother. 1998.-V.42.-P.1295−7.

10. Alcaide F. Molecular techniques in the diagnosis of drug-resistant tuberculosis / F. Alcaide, A. Telenti A. // Ann Acad Med Singapore. 1997. — V.26. — P. 647−50.

11. Alfredsen S. An outbreak of tuberculosis in pigs and cattle caused by Mycobacterium africanum / S. Alfredsen, F. Saxegaard // Vet Rec. 1992. — V.131. — P.51−53.

12. Anh D. Mycobacterium tuberculosis Beijing genotype emerging in Vietnam / D. Anh, M. Borgdorff, L. Van et al. // Emerg. Infect. Dis. 2000. — V.6. — P.302−5.

13. Antonova O. Detection of mutations in Mycobacterium tuberculosis genome determining resistance to fluoroquinolones by hybridization on biological microchips / O. Antonova, D. Gryadunov, S. Lapa et al. // Bull Exp Biol Med. 2008. — V.145. — P.108−13.

14. Aral S. Commercial sex work, drug use, and sexually transmitted infections in St. Petersburg, Russia / S. Aral, J. St Lawrence, R. Dyatlov, A. Kozlov // Soc Sei Med. 2005. — V.60(10). -P.2181−90.

15. Aranaz A. (a) Use of polymerase chain reaction in the diagnosis of tuberculosis in cats and dogs / A. Aranaz, E. Liebana, X. Pickering et al. // Vet Ree.- 1996. V.138(12). — P.276−80.

16. Aranaz A. (b) Spacer oligonucleotide typing of Mycobacterium bovis strains from cattle and other animals: a tool for studying epidemiology of tuberculosis / A. Aranaz, E. Liebana, A. Mateos et al. // J Clin. Microbiol. 1996. — V.34. P.2734- 40.

17. Arora J. Characterization of predominant Mycobacterium tuberculosis strains from different subpopulations of India / J. Arora, U. Singh, N. Suresh et al. // Infect Genet Evol. 2009. -V.9(5). — P. 832−9.

18. Aziz M. Epidemiology of antituberculosis drug resistance (the global project on antituberculosis drug resistance surveillance): an updated analysis / M. Aziz, A. Wright, A. Laszlo et al. // Lancet 2006. — V.368 — P.2142−54.

19. Banerjee A. inhA, a gene encodencoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis / A. Banerjee, E. Dubnau, A. Quemard et al. // Science 1994. -V.263 — P.227−30.

20. Barclay W. Mode of action of Isoniazid / W. Barclay, H. Ebert, D. Koch-Weser // Am. Rev. Tuberc. 1953. — V.67. -P.490−6.

21. Baulard A. Activation of the pro-drug ethionamide is regulated in mycobacteria / A. Baulard, J. Betts, J. Engohang-Ndong et al. // J Biol. Chem. 2000. — V.275. — P.28 326−31.

22. Bifani P. Global dissemination of the Mycobacterium tuberculosis W-Beijing family strains / P. Bifani, B. Mathema, N. Kurepina, B. Kreiswirth // Trends Microbiol. 2002. — V.IOP.45−52.

23. Bifani P. Origin and interstate spread of a New York City multidrug-resistant Mycobacterium tuberculosis clone family / P. Bifani, B. Plikaytis, V. Kapur et al. // JAMA 1996. — V.275. -P.452−7.

24. Bodmer T. Molecular basis of rifabutin susceptibility in rifampicin resistant M. tuberculosis./ T. Bodmer, G. Zurcher, I. Imboden, A. Telenti // J Antimicrob. Chemother. 1995. — V.35. -P.345−8.

25. Borsuk S. Molecular characterization of Mycobacterium tuberculosis isolates in a region of Brazil with a high incidence of tuberculosis / S. Borsuk, M. Dellagostin, M. Madeira et al. // Microbes and Infection. 2005. — V.7. — P. 1338−1344.

26. Brennan P. The envelope of Mycobacteria / P. Brennan, H. Nikaido // Annu Rev Biochem. -1995. V.64. — P.29−63.

27. Brosch R. A new evolutionary scenario for the Mycobacterium tuberculosis complex / R. Brosch, S. Gordon, M. Marmiesse et al. // Proc. Natl. Acad. Sei. USA 2002. — V.99. — 36 849.

28. Broussy S. 1H and 13C NMR characterization of hemiamidal isoniazid-NAD (H) adducts as possible inhibitors of InhA reductase of Mycobacterium tuberculosis / S. Broussy, Y. Coppel, M. Nguyen et’ai. // Chemistry 2003. — V.9. — P.2034;8.

29. Caminero J. Epidemiological evidence of the spread of a Mycobacterium tuberculosis strain of the Beijing genotype on Gran Canaria Island / J. Caminero, M. Pena, M. Campos-Herrero et al. //Am. J. Respir. Crit. Care Med. -2001. V. 164-P. 1165−70.

30. Campbell E. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase / E. Campbell, N. Korzheva, A. Mustaev et al. // Cell 2001. — V.104(6). — P.901−12.

31. Castets M. Tuberculosis bacilli of the African type: preliminary note / M. Castets, H. Boisvert, F. Grumbach et al. // Rev. Tuberc. Pneumol. (Paris). 1968. — V.32(2). — P. 178−84. French.

32. CDC. Centers for Disease Control and Prevention. Primary multidrug-resistant tuberculosisIvanovo Oblast, Russia, 1999. MMWR Morb Mortal Wkly Rep. 1999. — V.48(30). — P.661−4.

33. CDC. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs—worldwide, 2000;2004 // MMWR Morb Mortal Wkly Rep 2006. — V.55 — P.301−5.

34. Chaiprasert A. Intact pksl5/l in non-W-Beijing Mycobacterium tuberculosis isolates / A. Chaiprasert, J. Yorsangsukkamol, T. Prammananan et al. // Emerg. Infect. Dis. 2006. — V. 12. P.772−4.

35. Champoux J. DNA topoisomerases: structure, function, and mechanism / J. Champoux // Annu. Rev. Biochem. 2001. — V.70. — P.369−413.

36. Chan M. Seventy percent of the Mycobacterium tuberculosis isolates in Hong Kong represent the Beijing genotype / M. Chan, M. Borgdorff, C. Yip et al. // Epidemiol Infect. 2001. -V.127(l). — P.169−71.

37. Cho E. Detection of isoniazid and rifampicin resistance by sequencing of katG, inhA, and rpoB genes in Korea / E. Cho, H. Bae, S. Kang, E. Lee // Korean J Lab. Med. 2009. -V.29(5). — P.455−60.

38. Chouchane S. Catalaseperoxidase (Mycobacterium tuberculosis KatG) catalysis and isoniazid activation / S. Chouchane, I. Lippai, R. Magliozzo // Biochemistry 2000. — V.39. — P.9975−83.

39. Chuang P. Spoligotypes of Mycobacterium tuberculosis isolates of a high tuberculosis burden aboriginal township in Taiwan / P. Chuang, H. Liu, C. Sola et al. // Infect Genet Evol. 2008. V.8(5). P.553−7.

40. Cole S. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence / S. Cole, R. Brosch, J. Parkhill // Nature. 1998. — V.393. — P.537−44.

41. Collins C. The bovine tubercle bacillus / C. Collins // Br. J. Biomed. Sei. 2000. — V.57(3). -P. 234−40.

42. Collins C. Tuberculosis Bacteriology, Organization and Practice. 2nd ed. / C.H. Collins, J.M. Grange, M.D. Yates. Oxford: Butterworth-Heinemann. 1997.

43. Comas I. Genotyping of Genetically Monomorphic Bacteria: DNA Sequencing in Mycobacterium tuberculosis Highlights the Limitations of Current Methodologies / I. Comas, S. Homolka, S. Niemann, S. Gagneux //PLoS One. -2009. V.4(ll).: e7815.

44. Cooksey R. Characterization of streptomycin resistance mechanisms among Mycobacterium tuberculosis isolates from New York City / R. Cooksey, G. Morlock, A. Mcqueen et al. // Antimicrob. Agents Chemother. 1996. — V.40. — P. 1186−8.

45. Cousins D. Tuberculosis in seals caused by a novel member of the Mycobacterium tuberculosis complex: Mycobacterium pinnipedii sp. nov. / D. Cousins, R. Bastida, A. Cataldi et al. // Int J Syst Evol Microbiol. 2003. — V.53. — P.1305−14.

46. Cowan L. Evaluation of a two-step approach for large-scale, prospective genotyping of Mycobacterium tuberculosis isolates in the United States / L. Cowan, L. Diem, T. Monson et al. // J. Clin. Microbiol. 2005. — V.43 — P.688−95.

47. Cramer P. Multisubunit RNA polymerases. / P. Cramer. // Curr Opin Struct Biol. 2002. -V.12(l). — P.89−97.

48. Crawford J. Characterization of plasmids from strains of Mycobacterium avium-intracellulare. / J. Crawford, M. Cave, J. Bates // Rev. Infect. Dis. 1981. — V.3. — P.949−52.

49. Davies J. Misreading of ribonucleic acid code words induced by aminoglycoside antibiotics. The effect of drug concentration / J. Davies, B. Davis // J Biol. Chem. 1968. — V.243. -P.3312−6.

50. DeBarber A. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis / A. DeBarber, K. Mdluli, M. Bosman et al. // Proc. Natl Acad Sei USA 2000. -V.97. -P.9677−82.

51. Deretic V. Mycobacterium tuberculosis is a natural mutant with an inactivated oxidative-stress regulatory gene: implications for sensitivity to Isoniazid / V. Deretic, W. Philipp, S. Dhandayuthapani et al. // Mol Microbiol. 1995. — V. 17. — P.889−900.

52. Doroudchi M. IS6110-RFLP and spoligotyping of Mycobacterium tuberculosis isolates in Iran / M. Doroudchi, K. Kremer, E. Basiri et al. // Scand. J. Infect. Dis. 2000. — V.32. — P.663−8.

53. Drobniewski, F. (a). Drug-resistant tuberculosis, clinical virulence, and the dominance of the Beijing strain family in Russia / F. Drobniewski, Y. Balabanova, V. Nikolayevsky et al. // JAMA 2005. — V. 293 — P.2726−2731.

54. Drobniewski F. (b). Tuberculosis, HIV seroprevalence and intravenous drug abuse in prisoners / F. Drobniewski, Y. Balabanova, M. Ruddy et al. // Eur Respir J 2005. — V.26 — P. 298 304.

55. Duong D. Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam / D. Duong, T.H. Nguyen., T.N. Nguyen et al. J. Antimicrob. Agents Chemother. 2009. — V.53(l 1). — P.4835−9.

56. Eisenach K. Repetitive DNA sequences as probes for Mycobacterium tuberculosis / K. Eisenach, J. Crawford, J. Bates // J. Clin. Microbiol. 1988. — V.26. — P.2240−5.

57. Escuyer V. The role of the embA and embB gene products in the biosynthesis of the terminal hexaarabinofuranosyl motif of Mycobacterium smegmatis arabinogalactan / V. Escuyer, M. Lety, J. Torrelles et al // J. Biol. Chem. 2001. — V.276. — P.48 854−62.

58. Filliol, I. Global distribution of Mycobacterium tuberculosis spoligotypes / I. Filliol, J. Driscoll, D. van Soolingen et al. // Emerg. Inf. Dis. 2002 — V.8. — P. 1347−50.

59. Frothingham R. Extensive DNA sequence conservation throughout the Mycobacterium tuberculosis complex / R. Frothingham, H. Hills, K. Wilson // J. Clin. Microbiol. 1994. -V.32.-P. 1639−43.

60. Frothingham R. Genetic diversity in the Mycobacterium tuberculosis complex based on variable numbers of tandem DNA repeats / R. Frothingham, W. Meeker-O'Connell // Microbiol 1998. — V.144 — P.1189−1196.

61. Gagneux S. Variable host-pathogen compatibility in Mycobacterium tuberculosis / S. Gagneux, K. Deriemer, T. van et al. // Proc. Natl. Acad. Sei. USA 2006. — V.103. — P.2869−73.

62. Gandhi N. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa / N. Gandhi, A. Moll, A. Sturm et al. // Lancet 2006. — V.368(9547). — P. 1575−80.

63. Gangadharam P. The effects of exposure time, drug concentration, and temperature on the activity of ethambutol versus Mycobacterium tuberculosis / P. Gangadharam, P. Pratt, V. Perumal, M. Iseman // Am. Rev. Respir. Dis. 1990. — V. 141. — P. 1478−82.

64. Gamier T. The complete genome sequence of Mycobacterium bovis / T. Gamier, K. Eiglmeier, J. Camus et al. // Proc. Natl. Acad. Sei. USA 2003. — V. 100. — P.7877−82.

65. Garvin R. The effects of streptomycin or dihydrostreptomycin binding to 16S rRNA or to 30S ribosomal subunits / R. Garvin, D. Biswas, L. Gorini // Proc. Natl Acad. Sei USA 1974. -V.71. — P.3814−8.

66. Ghiladi R. Superoxide reactivity of KatG: insights into isoniazid resistance pathways in TB / R. Ghiladi, D. Cabelli, P. Ortiz De Montellano // J. Am. Chem. Soc. 2004. — V.126. -P.4772−3.

67. Ginsburg A. Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model / A. Ginsburg, R. Sun, H. Calamita et al. // Antimicrob. Agents Chemother. 2005. — V.49. — P.3977−9.

68. Glynn J. Worldwide occurrence of Beijing/W strains of Mycobacterium tuberculosis: a systematic review / J. Glynn, J. Whiteley, P. Bifani et al. //Emerg Infect Dis 2002. — V.8. -P.843−9.

69. Glynn J. Mycobacterium tuberculosis Beijing genotype, northern Malawi / J. Glynn, A. Crampin, H. Traore et al. // Infect. Dis. 2005. — V. l 1. — P. 150−3.

70. Gordon S. New insertion sequences and a novel repeated sequence in the genome of Mycobacterium tuberculosis H37Rv / S. Gordon, B. Heym, J. Parkhill et al. // Microbiology -1999. V. 145.-P.881−91.

71. Guo H. Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA / H. Guo, Q. Seet, S. Denkin et al. // J Med Microbiol. 2006. -V.55(ll). -P.1527−31.

72. Hannan M. Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States / M. Hann, E. Desmond, G. Morlock et al. // J Clin Microbiol. 2001. — V.39. — P.647−50.

73. Heep M. Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis / M. Heep, U. Rieger, D. Beck, N. Lehn // Antimicrob. Agents Chemother. 2000. — V.44(4). — P. 1075−7.

74. Heimer R. Estimation of the number of injection drug users in St. Petersburg, Russia / R. Heimer, E. White//Drug Alcohol Depend. -2010. V. l 09(1−3). -P.79−83.

75. Hegde S. A fluoroquinolone resistance protein from Mycobacterium tuberculosis that mimics DNA / S. Hegde, M. Vetting, S. Roderick et al. // Science 2005. — V.308(5727). — P. 1480−3.

76. Heinz C. Purification of porins from Mycobacterium smegmatis / C. Heinz, E. Roth, M. Niederweis // Methods Mol. Biol. 2003. — V.228. — P.139−50.

77. Hewlett D. Jr.. Outbreak of multidrug-resistant tuberculosis at a hospital—New York City, 1991 / D. Hewlett Jr., D. Franchini, D. Horn et al. // MMWR Morb Mortal Wkly Rep. 1993. — V.42. — P.427−33.

78. Hirano K. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis / K. Hirano, M. Takahashi M, Y. Kazumi et al. // Tuberc. Lung Dis.- 1997,-V.78.-P.117−22.

79. Hirsh A. Stable association between strains of Mycobacterium tuberculosis and their human host populations / A. Hirsh, A. Tsolaki, K. DeRiemer et al. // Proc. Natl. Acad. Sei. USA -2004. V. l01. -P.4871−6.

80. Hoashi S. pncA gene mutations in clinical isolates of tubercle bacillus by polymerase chain reaction direct sequencing method: in relationship to pyrazinamide resistance / S. Hoashi, H. Tai, M. Tamari // Kekkaku 1999. — V.74. — P.441−5.

81. Hoffman C. Disclosure of the mycobacterial outer membrane: cryo-electron tomography and vitreous sections reveal the lipid bilayer structure / C. Hoffmann, A. Leis, M. Niederweis et al. // Proc. Natl. Acad. Sei. USA.- 2008. V.105 (10). — P. 3963−7.

82. Hofling C. Prevalence of katG Ser315 substitution and ipoB mutations in isoniazid-resistant Mycobacterium tuberculosis isolates from Brazil / C. Hofling, E. Pavan, C. Giampaglia et al. // Int. J Tuberc. Lung Dis. 2005. — V.9(l). — P.87−93.

83. Hou L. Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China / L. Hou, D. Osei-Hyiaman, Z. Zhang et al. // Epidemiol. Infect. -2000. V. 124.-P.227−32.

84. Huitema H. Mycobacterium microti infection in a cat and some pigs / H. Huitema, F. Jaartsveld // Antonie Leeuwenhoek. 1967. — V.33. — 209−12.

85. Inderlied C. Antimycobacterial agents and susceptibility tests. C. Inderlied, M. Salfinger In: Manuals of clinical microbiology. Eds: Murray P R, Baron E J, Pfaller M A, Tenover F C, Yolken RH. 1999. P.1601−23.

86. Jakubowiak W. Risk factors associated with default among new pulmonary TB patients and social support in six Russian regions / W. Jakubowiak, E. Bogorodskaya, S. Borisov et al. // Int. J. Tuberc. Lung Dis. 2007. — V. l 1(1) — P.46−53.

87. Jarlier V. Mycobacterial cell wall: structure and role in natural resistance to antibiotics / V. Jarlier, H. Nikaido // FEMS Microbiol. Lett. 1994. — V.123 (1−2). — P. l 1−8.

88. Jiao W. Molecular characteristics of rifampin and isoniazid resistant Mycobacterium tuberculosis strains from Beijing, China / W. Jiao, I. Mokrousov, G. Sun et al. // Chin. Med. J (Engl). 2007. — V. l20(9). — P.814−9.

89. Johansen S. Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2'-O-methylations in 16S and 23S rRNAs / S. Johansen, C. Maus, B. Plikaytis et al. // Mol. Cell.- 2006.-V.23.-P. 173−82.

90. Johnsson K. Mechanistic studies of the oxidation of isoniazid by the catalase-peroxidase from Mycobacterium tuberculosis / K. Johnsson, P. Schultz // J Am. Chem. Soc. 1994. — V. l 16. -P.7425−6.

91. Johnsson K. Studies on the mechanism of action of isoniazid and ethionamide in the chemotherapy of tuberculosis / K. Johnsson, D. King, P. Schultz // J Am. Chem. Soc. 1995. V. l 17. P.5009−10.

92. Kamerbeek J. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology / J. Kamerbeek, L. Schouls, A. Kolk et al. // J Clin. Microbiol.- 1997. V.35. — P.907−14.

93. Kazionny B. Implications of the growing HIV-1 epidemic for tuberculosis control in Russia / B. Kazionny, C. Wells, H. Kluge et al. // Lancet 2001 — V.358 — P.1513−4.

94. Kelley C. Analysis of ahpC gene mutations in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis / C. Kelley, D. Rouse, S. Morris // Antimicrob. Agents Chemother. 1997. — V.41. — P.2057;8.

95. Kenney T. Cloning and sequence analysis of the rpsL and rrsG genes of Mycobacterium smegmatis and characterization of mutations causing resistance to streptomycin / T. Kenney, G. Churchward // J Bacterid. 1994. — V.176. — P.6153−6.

96. Kimerling M. Inadequacy of the current WHO re-treatment regimen in central Siberian prison: treatment failure and MDR-TB / M. Kimerling, H. Kluge, N. Vezhnina // Int. J. Tuberc. Lung Dis. 1999.-V.3-P.451−3.

97. Kimerling M. The risk of MDR-TB and polyresistant tuberculosis among the civilian population of Tomsk city, Siberia, 1999 / M Kimerling, A. Slavuckij, S. Chavers // Int. J. Tuberc. Lung Dis. 2003. — V.7 — P.866−72.

98. Kimura M. The neutral theory of molecular evolution. Cambridge (UK): Cambridge University Press. 1983.

99. Kirschner P. Genotypic identification of mycobacteria by nucleic acid sequence determination: report of a 2-year experience in a clinical laboratory / P. Kirschner, B. Springer, U. Vogel et al. // J. Clin. Microbiol. 1993. — V.31. — P.2882−89.

100. Konno K. Pyrazinamide susceptibility and amidase activity of tubercle bacilli / K. Kinno, F. Feldman, W. McDermott // Am. Rev. Respir. Dis. 1967. — V.95. — P.461−9.

101. Kovalev S. Genetic analysis of Mycobacterium tuberculosis strains isolated in Ural region, Russian Federation, by MIRU-VNTR genotyping / S. Kovalev, E. Kamaev, M. Kravchenko et al. // Int. J. Tuberc. Lung Dis. 2005. — V.9 — P.746−752.

102. Krapitsky E. The onset of HIV infection in the Leningrad region of Russia: a focus on drug and alcohol dependence / E. Krupitsky, E. Zvartau E, G. Karandashova et al. // HIV Med. -2004 V.5-P. 30−3.

103. Kruuner A. Spread of drug-resistant pulmonary tuberculosis in Estonia / A. Kruuner, S. Hoffner, H. Sillastu, M. Danilovits et al. //J Clin. Microbiol. 2001. — V. 39 — P.3339 -45.

104. Kubica T. The Beijing genotype is a major cause of drug-resistant tuberculosis in Kazakhstan / T. Kubica, R. Agzamova, A. Wright et al. // Int. J Tuberc. Lung Dis. 2005. — V. 9(6). -P.646−53.

105. Kubica T. The Beijing genotype is emerging among multidrug-resistant Mycobacterium tuberculosis strains from Germany/ T. Kubica, S. Riisch-Gerdes, S. Niemann // Int. J. Tuberc. Lung Dis. 2004. — V.8 — P. 1107−13.

106. Kwon H. Distribution and characterization of (3-lactamases of mycobacteria and related organisms / H. Kwon, H. Tomioka, H. Saito // Tuberc. Lung Dis. 1995. — V.76. — P.141−8.

107. Lafontaine D. Treatment of multidrug-resistant tuberculosis in Rassian prisons / D. Lafontaine, A. Slavuski, N. Vazhnina, O. Sheyanenko // Lancet 2004. — V.363 — P.246−7.

108. Lari N. Mutations in mutt genes of Mycobacterium tuberculosis isolates of Beijing genotype / N. Lari, L. Rindi, D. Bonanni et al. // J Med. Microbiol. 2006. — V.55. — P.599−603.

109. Lavender C. Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis isolates collected in Australia / C. Lavender, M. Globan, A. Sievers et al. // Antimicrob. Agents Chemother. 2005. — V.49. — P.4068−74.

110. Lefford M. The ethionamide sensitivity of British pre-treatment strains of Mycobacterium tuberculosis / M. Lefford // J. Tubercle 1966. — V.47. — P. 198−206.

111. Lei B. Action mechanism of antitubercular isoniazid. Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of InhA inhibitor / B. Lei, C. Wei, S. Tu // J Biol. Chem. 2000. — V.275. — P.2520−6.

112. Leimane V. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study / V. Leimane, V. Riekstina, T. Holtz et al. // Lancet 2005 -V.365-P.318−26.

113. Liu S. Canine tuberculosis / S. Liu, I. Weitzman, G. Johnson // J Am Vet Med Assoc. 1980. -V. 177(2).-P. 164−7.

114. LoBue P. Tuberculosis in humans and animals: an overview / P. LoBue, D. Enarson, C. Thoen. // Int. J. Tuberc. Lung Dis. 2010. — V.14(9). — P. 1075−8.

115. Lopez B. A marked difference in pathogenesis and immune response induced by different Mycobacterium tuberculosis genotypes / B. Lopez, D. Aguilar, H. Orozco et al. // Clin. Exp. Immunol. 2003. — V. 133(1). -P.30−7.

116. Love J. Molecular epidemiology of tuberculosis in England, 1998 / J. Love, P. Sonnenberg, J. Glynn et al. // Int. J Tuberc. Lung Dis. 2009 — V.13(2). — P.201−7.

117. Lukat-Rodgers G. Carbon monoxide adducts of KatG and KatG (S315T) as probes of the heme site and isoniazid binding / G. Lukat-Rodgers, N. Wengenack, F. Rusnak, K. Rodgers // Biochemistry 2001. — V.40. — P.7149−57.

118. Lukat-Rodgers G. Spectroscopic comparison of the heme active sites in WT KatG and its S315T mutant / G. Lukat-Rodgers, N. Wengenack, F. Rusnak, K. Rodgers // Biochemistry -2000. V.39. — P.9984−93.

119. Magliozzo R. Evidence for isoniazid oxidation by oxyferrous mycobacterial catalase-peroxidase / R. Magliozzo, J. Marcinkeviciene // J Am. Chem. Soc. 1996. — V.118. -P.l1303−4.

120. Martin C. Transposition of an antibiotic resistant element in mycobacteria / C. Martin, J. Timm, J. Rauzier et al. //Nature 1990. — V.345 — P.739−43.

121. Marttila H. pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis isolates from northwest Russia / H. Marttila, M. Marjamaki, E. Vyshnevskaya et al. // Antimicrob. Agents Chemother. 1999. — V.43. — P.1764−6.

122. Maus C. Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis / C. Maus, B Plikaytis, T. Shinnick // Antimicrob. Agents Chemother. 2005. — V.49. — P.571−7.

123. Mazars E. High-resolution minisatellite-based typing as a portable approach to global analysis of Mycobacterium tuberculosis molecular epidemiology / E. Mazars, S. Lesjean, A. Banuls et al. //Proc. Natl. Acad. Sei. USA 2001. -V.98. -P.1901;6.

124. McDermott W. Activation of pyrazinamide and nicotinamide in acidic environments in vitro / W. McDermott, R. Tompsett / Am. Rev. Tuberc. 1954. — V.70. — P.748−54.

125. Mdluli K. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by Isoniazid / K. Miduli, R. Slayden, Y. Zhu et al. // Science 1998. — V.280. — P.1607−10.

126. Michalak K. Mycobacterium tuberculosis infection as a zoonotic disease: transmission between humans and elephants / K. Michalak, C. Austin, S. Diesel, et al. // Emerg. Infect. Dis.- 1998. V.4. — P. 283−287.

127. Middlebrook G. INH resistance and catalase activity of the tubercle bacilli / G. Middlebrook // Am. Rev. Tuberc. 1954. — V.69. — P.471−2.

128. Mitchison D. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis / D. Mitchison, A. Nunn // Am. Rev. Respir. Dis. 1986. — V.133. P.423−30.

129. Mitchison D. The action of antituberculosis drugs in short course chemotherapy / D. Mitchison // Tubercle 1985. — V.66. — P.219−25.

130. Mitchison D. The bactericidal activities of antituberculous drags / D. Mitchison, J. Selkon // Am. Rev. Tuberc. 1956. — V.74(2). — P. 109−16.

131. Mokrousov L (d). Phylogenetic reconstruction within Mycobacterium tuberculosis Beijing genotype in northwestern Russia /1. Mokrousov, O. Narvskaya, T. Otten T // Res. Microbiol.- 2002. V. 153 — P.629−637.

132. Mokrousov I. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia / I. Mokrousov, T. Otten, O. Manicheva et al. // Antimicrob. Agents Chemother. 2008. — V. 52(8). — P.2937−9.

133. Morcillo N. First description of Mycobacterium tuberculosis Beijing genotype in Argentina / N. Morcillo, B. Di Giulio, C. Chirico et al. // Rev. Argent. Microbiol. 2005. — V.37. — P.92−5.

134. Morlock G. Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis / G. Morlock, J. Crawford, W. Butler et al. // Antimicrob. Agents Chemother. 2000. — V.44. -P.2291−5.

135. Mostowy S. Genomic deletions suggest a phylogeny for the Mycobacterium tuberculosis complex / S. Mostowy, D. Cousins, J. Brinkman et al. // J Infect. Dis. 2002. -V.186. -P.74−80.

136. Mostowy S. The origin and evolution ofMycobacterium tuberculosis / S. Mostowy, M. Behr // Clin Chest Med. 2005. — V.26(2). — P.207−16.

137. Murakami K. Bacterial RNA polymerases: the wholo story / K. Murakami, S. Darst // Curr. Opin. Struct. Biol. -2003. -V.13(l).-P.31−9.

138. Niederweis M. Mycobacterial outer membranes: in search of proteins / M. Niederweis, O. Danilchanka, J. Huff et al. // Trends Microbiol. 2010. — V. 18 (3). P. 109−16.

139. Niederweis M. Mycobacterial porins—new channel proteins in unique outer membranes / M. Niederweis // Mol.Microbiol. 2003. — V.49(5). — P. 1167−77.

140. Okamoto S. Loss of a conserved 7-methylguanosine modifi cation in 16S rRNA confers low-level streptomycin resistance in bacteria / S. Okamoto, A. Tamara, C. Nakajima et al. // Mol. Microbiol. -2007. -V.63. P. 1096−1106.

141. Palittapongarnpim P. Restriction fragment length polymorphism study of Mycobacterium tuberculosis in Thailand using IS6110 as probe / P. Palittapongarnpim, P. Luangsook, S. Tansuphaswadikul et al. // Int. J. Tuberc. Lung Dis. 1997. — V.l. — P.370−6.

142. Park S. pncA mutations in clinical Mycobacterium tuberculosis isolates from Korea / S. Pakr, J. Lee, C. Chang et al. // BMC Infect Dis. 2001. — V.l. — P.4.

143. Park Y. Comparison of drug resistance genotypes between Beijing and non-Beijing family strains of Mycobacterium tuberculosis in Korea / Y. Park, S. Shin, S. Ryu et al. // J Microbiol. Methods 2005. — V.63. — P. 165−72.

144. Parsons L. Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCR-based genomic deletion analysis / L. Parsons, R. Brosch R, S. et al. // J Clin. Microbiol. 2002. — V.40(7). — P.2339−45.

145. Parwati I. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains /1. Parwati, R. van Crevel, D. van Soolingen // Lancet Infect. Dis. 2010. -V. 10(2). — P. 103−11.

146. Pattyn S. Mycobacterium microti infection in vicuna (Lama vicugna) / S. Pattyn, F. Portaels, P. Kageruca, P. Gigase // Acta Zoo 1 Pathol Antverp. 1970. — V.51. — P. 17−24.

147. Pearson M. Nosocomial transmission of multi-drug resistant Mycobacterium tuberculosis. A risk to patients and health care workers / M. Pearson, J. Jereb, T. Frieden et al. // Ann. Intern. Med. 1992. — V. 117. — P. 191−6.

148. Qian L. Retrospective Analysis of the Beijing Family of Mycobacteriumtuberculosis in Preserved Lung Tissues / L. Qian, A. van Embden, A. van der Zanden et al. // J Clin. Microbiol. 1999. — V.37(2). — P. 471−4.

149. Rad M. Mutations in putative mutator genes of Mycobacterium tuberculosis strains of the W-Beijing family / M. Rad, P. Bifani, C. Martin et al. // Emerg. Infect. Dis. 2003. — V.9. -P.838−45.

150. Reed M. Major Mycobacterium tuberculosislineages associate with patient country of origin / M. Reed, V. Pichler, F. Mcintosh et al. // J Clin. Microbiol. 2009. — V.47. — 1119−28.

151. Reed M. The W-Beijing lineage of Mycobacterium tuberculosis overproduces triglycerides and has the DosR dormancy regulon constitutively upregulated / M. Reed, S. Gagneux, K. Deriemer et al. // J Bacteriol. 2007. — V. 189. — P.2583−9.

152. Rigouts L. Newly developed primers for comprehensive amplification of the rpoB gene and detection of rifampin resistance in Mycobacterium tuberculosis / L. Rigouts, O. Nolasco, P. de Rijk et al. // J Clin Microbiol. 2007. — V.45(l). — P.252−4.

153. Ross B. Molecular cloning of a highly repeated DNA element from Mycobacterium tuberculosis and its use as an epidemiological tool / B. Ross, K. Raios, K. Jackson et al. // J Clin. Microbiol. 1992. — V (30). — P.942- 6.

154. Rouse D. Molecular mechanisms of isoniazid resistance in Mycobacterium tuberculosis and Mycobacterium bovis / D. Rouse, S. Morris // Infect. Immun. 1995. — V.63. — P. 1427−33.

155. Rouse D. Site-directed mutagenesis of the katG gene of Mycobacterium tuberculosis: effects on catalase-peroxidase activities and isoniazid resistance / D. Rouse, J. DeVito, Z. Li et al. // Mol. Microbiol. 1996. — V.22(3). — P.583−92.

156. Sachais B. Novel pncA mutations in pyrazinamide-resistant isolates of Mycobacterium tuberculosis / B. Sachais, I. Nachamkindagger, J. Mills, D. Leonard // Mol. Diagn. 1998. -V.3. -P.229−31.

157. Sandven P. Abstract from the 29th World Conference of the International Union Against Tuberculosis and Lung Disease / P. Sandven, D. Caugant, A. Mariandyshev et al. // Int. J. Tuberc. Lung Dis. 1998. — V.2 (suppl.2). — P.280.

158. Scorpio A. (a). Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis / A. Scorpio, P. Lindholm-Levy, L. Heifets et al. // Antimicrob. Agents Chemother. 1997. — V.41. -P.540−3.

159. Scorpio A. Mutations in pncA, a gene encoding pyrazinamidase/ nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus / A. Scorpio, Y. Zhang. // Nature Med. 1996. — V.2. — P.662−7.

160. Shah N. Worldwide emergence of extensively drug-resistant tuberculosis / N. Shah, A. Wright, G. Bai et al. // Emerg. Infect. Dis. 2007. — V.13 -P.380−7.

161. Shemyakin I. Characterization of drug-resistant isolates of Mycobacterium tuberculosis derived from Russian inmates / I. Shemyakin, V. Stepanshina, I. Ivanov et al. // Int. J Tuberc. Lung Dis. 2004. — V.8(10). — P. 1194−203.

162. Shen L. (a). Mechanism of quinolone inhibition of DNA gyrase. Appearance of unique norfloxacin binding sites in enzyme-DNA complexes / L. Shen, W. Kohlbrenner, D. Weigl, J. Baranowski // J. Biol. Chem. 1989. — V.264. — P.2973−8.

163. Shen L. (b). Mechanism of inhibition of DNA gyrase by quinolone antibacterials: specificity and cooperativity of drug binding to DNA / L. Shen, J. Baranowski, A. Pernet // Biochemistry- 1989. -V. 28. P.3879−85.

164. Shen L. ©. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug~DNA binding model / L. Shen, L. Mitscher, P. Sharma et al. // Biochemistry- 1989.-V.28.-P.3886−89.

165. Shen L. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA / L. Shen, A. Pernet // Proc. Natl. Acad. Sei. -1985. V.82. — P.307−11.

166. Shilova M. The resurgence of tuberculosis in Russia. / M. Shilova, C. Dye // Philos Trans R Soc Lond В Biol Sei. 2001. — V.356(1411). — P. 1069−75.

167. Siddiqi N. Molecular Characterization of Multidrug-Resistant Isolates of Mycobacterium tuberculosis from Patients in North India / N. Siddiqi, M. Shamim, S. Hussain et al. // Antimicrob Agenta and Chemother 2002. — V.46 — P. 443−50.

168. Siddiqi S. Antimicrobial susceptibility testing: radiometric (BACTEC) tests for slowly growing mycobacteria. In: Clinical Microbiology Procedure Handbook. Eds: Isenberg H D, ASM Press, Washington D.C., 1992. P. 14−25.

169. Silva M. Mutations in katG, inhA, and ahpC genes of Brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis / M. Silva, S. Senna, M. Ribeiro et al. // J Clin. Microbiol. -2003. V.41(9). — P.4471−4.

170. Silva M. The interpretation of the ultrastructure of Mycobacterial cells in transmission electron microscopy of ultrathin sections / M. Silva, P. Macedo // Int. J. Lepr. 1983. — V.51. P.225−234.

171. Singh M. Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates / M. Singh, G.P.S. Jadaun, Ramdas et al. // Indian J Med Res. 2011 — V.133. — P.535−40.

172. Singh U. Predominant Tuberculosis Spoligotypes, Delhi, India / U. Singh, N. Suresh, N. Vijaya Bhanu et al. // Emerg. Infect. Dis. -2004. V.10(6). -P.l 138−42.

173. SITVIT2. http://www.pasteur-euadeloupe.fi-.8Q81/SITVITDemo/index.isp. Дата обращениямарт 2011 г.

174. Soini Н. Characterization of Mycobacterium tuberculosis isolates from patients in Houston, Texas, by spoligotyping // H. Soini, X. Pan, A. Amin et al. // J. Clin. Microbiol. 2000 -V.38. -P.669−76.

175. Sola C. Tuberculosis in the Caribbean: using spacer oligonucleotide typing to understand strain origin and transmission / C. Sola, A. Devallois, L. Horgen et al. //. Emerg. Infect. Dis. -1999. — V.5. P. 404−14.

176. Sola, С. Spoligotype database of Mycobacterium tuberculosis: biogeographical distribution of shared types and epidemiological and phylogenetic perspectives / C. Sola, I. Filliol, C. Guttierez, et al. // Emerg. Infect. Dis. 2001. — V.7. — P.390−6.

177. Somoskovi A. The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis / A. Somoskovi, L. Parsons, M. Salfinger // Respir. Res. 2001. — V.2. — P. 164−8.

178. Spindola de Miranda S. Mutations in the rpoB gene of rifampicin-resistant Mycobacterium tuberculosis strains isolated in Brazil and France / S. Spindola de Miranda, A Kritski, I. Filliol et al. // Mem. Inst. Oswaldo Cruz. 2001. — V. 96(2). — P.247−50.

179. SPOTCLUST. http://tbinsight.cs.rpi.edu/run spotclusthtml.. Дата обращения март 2011 г.

180. Sreevatsan S. (a). Identification of a polymorphic nucleotide in oxyR specific for Mycobacterium bovis / S. Sreevatsan, P. Escalante, X. Pan et al. // J Clin Microbiol.1996. — V.34. P.2007;10.

181. Sreevatsan S. (b) Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms / S. Sreevatsan, X. Pan, Y. Zhang et al. // Antimicrob. Agents Chemother. 1997. — V.41. — P.636−40.

182. Sreevatsan S. ©. Ethambutol resistance in Mycobacterium tuberculosis: critical role of embB mutations / S. Sreevatsan, K. Stochbauer, X. Pan et al. // Antimicrob. Agents Chemother.1997. -V.41.-P.1677−81.

183. Stem V. Problems in prisons worldwide, with a particular focus on Russia / V. Stem // Ann. N Y Acad. Sei. 2001. — V.953. — P. 113−9.

184. Sulochana S. Analysis of fluoroqunolone resistance in clinical isolates of Mycobacterium tuberculosis from India / S. Sulochana, S. Narayanan, CN Paramasivan et al. // J. Chemother. -2007 V.19 — P.89−93.

185. Sun Z. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates / Z. Sun, J. Zhang, X. Zhang et aL // Int. J. Antimicrob. Agents. 2008. — V.31. — P. l 15−121.

186. Surikova O. Efficient differentiation of Mycobacterium tuberculosis strains of the W-Beijing family from Russia using highly polymorphic VNTR loci / O. Surikova, D. Voitech, G. Kuzmicheva et al. // Eur. J. Epidemiol. 2005. — V.20 — P.963−974.

187. Suzuki Y. Detection of k anamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene / Y. Suzuki, C. Katsukawa, A. Tamara et al. // J Clin. Microbiol. 1998. — V.36. — P. 1220−5.

188. Takayama K. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis / K. Takayama, J. Kilburn // Antimicrob. Agents Chemother. 1989. — V. 33. -P. 1493−9.

189. Takiff H. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations / H. Takiff, L. Salazar, C. Guerrero et al. // Antimicrob. Agents Chemother. 1994. — V.38(4). — P.773−80.

190. Taniguchi H. Rifampicin resistance and mutation of the rpoB gene in Mycobacterium tuberculosis / H. Taniguchi, H. Aramaki, Y. Nikaido et al. // FEMS Microbiol. Lett. 1996. -V.144. — P. 103−8.

191. Tarshis M. Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media / M. Tarshis, W. Weed // Am. Rev. Tuberc. -1953. V.67. — P.391−5.

192. Telenti A. The emb operon, a unique gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol / A. Telenti, W. Phillipp, S. Sreevatsan et al. // Nat. Med. 1997. -V.3. -P.567−70.

193. Thierry D. (a). Characterization of a Mycobacterium tuberculosis insertion sequence, IS6110, and its application in diagnosis / D. Thierry, A. Brisson-Nod, V. Vincent-Levy-FrWbault et al. // J. Clin. Microbiol. 1990. — V. 28 — P.2668−73.

194. Thierry D. (b). S6110, an IS-like element of Mycobacterium tuberculosis complex / D. Thierry, M. Cave, K. Eisenach et al. // Nucleic Acids Res. 1990. — V.18 — P. 188.

195. Thorel M. Isolation of Mycobacterium africanum from monkeys / M. Thorel // Tubercle. -1980. V.6(2). -P.101−4.

196. Toungoussova O. Spread of drug-resistant Mycobacterium tuberculosis strains of the Beijing genotype in the Archangel Oblast, Russia / O. Toungoussova, P. Sandven, A. Mariandyshev et al. // J Clin. Microbiol. 2002. — V.40(6). — P. 1930;7.

197. Trias J. Permeability of the cell wall of Mycobacterium smegmatis / J. Trias, R. Benz // Mol. Microbiol. 1994. — V. 14(2). -P.283−90.

198. Trias J. Porins in the cell wall of Mycobacteria / J. Trias, V. Jarlier, R. Benz. // Science. -1992,-V.258(5087). P. 1479−81.

199. Turett G. Improved outcomes for patients with multidrug-resistant tuberculosis / G. Turett, E. Telzak, L. Torian et al. // Clin. Infect. Dis. 1995. — V.21. — P.1238−44.

200. Vannelli T. The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase / T. Vannelli, A. Dykman, P. Ortiz de Montellano // J Biol. Chem. 2002. -V.277. P. 12 824−9.

201. Wade M. Mechanisms of drug resistance in Mycobacterium tuberculosis / M. Wade, Y. Zhang // Front Biosci. 2004. — V.9. — P.975−94.

202. Welinder K. Bacterial catalase-peroxidases are gene duplicated members of the plant peroxidase superfamily / K. Welinder // Biochim. Biophys. Acta. 1991. — V.1080(3). -P.215−20.

203. Wengenack N. Evidence for differential binding of isoniazid by Mycobacterium tuberculosis KatG and the isoniazid-resistant mutant KatG (S315T)/ N. Wengenack., S. Todorovic, L. Yu, F. Rusnak // Biochemistry 1998. — V.37. — P.15 825−34.

204. Wengenack N. Evidence for Isoniazid-dependent free radical generation catalyzed by Mycobacterium tuberculosis KatG and the Isoniazid-resistant mutant KatG (S315T) / N. Wengenack, F. Rusnak // Biochemistry 2001. — V.40. — P.8990−6.

205. Wengenack N. Recombinant Mycobacterium tuberculosis KatG (S315T) is a competent catalase-peroxidase with reduced activity toward isoniazid / N. Wengenack, J. Uhl, A. St Amand et al. // J. Infect. Dis. 1997. — V. 176. — P.722−7.

206. Williams D. Characterization of rifampin-resistance in pathogenic mycobacteria / D. Williams, C. Waguespack, K. Eisenach et al. // Antimicrob. Agents Chemother. 1994. -V.38. — P.2380−86.

207. Williams D. Contribution of rpoB mutation to development of rifamycin crossresistance in Mycobacterium tuberculosis / D. Williams, L. Spring, L. Collins et al. // Antimicrob. Agents Chemother. 1998. — V.42. — P. 1853−7.

208. Winder F. The antibacterial action of streptomycin, isoniazid, and PAS/ F. Winder // Chemotherapy of tuberculosis, ed. V.C.London: Butterworths, 1964. P. l 11−49.

209. World Health Organization. WHO report 2004. Global Tuberculosis Control 2004 — Geneva, Switzerland.

210. World Health Organization. WHO Report 2010 Global Tuberculosis Control 2010. -Geneva, Switzerland.

211. Wu X. Detection of the mutations in katG 315 and inhA -15 of Mycobacterium tuberculosis strains isolated from Chinese patients / X. Wu, Y. Lu. J. Zhang et al. // Chin Med J (Engl). -2006. -V. 119(3). -P.230−3.

212. Yao C. Detection of rpoB, katG and inhA gene mutations in Mycobacterium tuberculosis clinical isolates from Chongqing as determined by microarray / C. Yao, T. Zhu, Y. Li et al. // Clin Microbiol Infect. 2010. — V.16(l 1). — P. 1639−43.

213. Yoshida H. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli / H. Yoshida, M. Bogaki M., M. Nakamura, S. Nakamura // J. Antimicrob. Agents Chemother. 1990. — V.34. — P.1271−2.

214. Youatt J. A review of the action of Isoniazid / J. Youatt // Am. Rev. Respir. Dis. 1969. -V.99(5). — P.729−49.

215. Yu S. Reduced affinity for Isoniazid in the S315T mutant of Mycobacterium tuberculosis KatG is a key factor in antibiotic resistance / S. Yu., S. Girotto, C. Lee, R. Magliozzo // J. Biol. Chem. 2003. — V.278. — P.14 769−75.

216. Zainuddin Z. Polymorphic repetitive DNA sequences in Mycobacterium tuberculosis detected with a gene probe from a Mycobacterium fortum plasmid / Z. Zainuddin, J. Dale // J. Gen. Microbiol. 1989 — V. 135 — P.2347−2355.

217. Zhang Y. Mechanisms of drug resistance in Mycobacterium tuberculosis / Y. Zhang, W. Yew // Int. J Tuberc. Lung Dis. 2009. — V.13(l 1). — P.1320−30.

218. Zhang Y. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis / Y. Zhang, B. Heym, B. Allen et al. // Nature 1992. — V.358. — P.591−3.

219. Zignol M. Global incidence of multidrag-resistant tuberculosis / M. Zignol, M. Hosseini, A. Wright et al. // J. Infect. Dis. 2006. — V.194 -P.479−85.

220. Номер изолята Код изолята на дендрограмме Год сбора образца Возбудитель Пол/возраст пациента Код сполиготипа в базе данных SpolDB4 Семейство сполиготипов Лекарственная устойчивость* Комментарии*.

221. Нуклеотидная последовательность фрагмента гена katG, несущая мутации, ассоциированные с устойчивостью микобактерий к изониазиду.